

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for transducing a gene into activated ~~CD8+~~ T cells, wherein said method comprises the ~~step of~~ steps of:

(a) contacting a paramyxovirus vector carrying the gene with activated ~~CD8+~~ T cells, and

(b) detecting and/or purifying activated T cells transduced with the gene.

2. (Original) The method according to claim 1, wherein the paramyxovirus vector is a Sendai virus vector.

3-8. (Cancelled)

9. (Previously Presented) The method according to claim 1, wherein the activated T cells are antigen-activated T cells.

10. (Withdrawn) The method according to claim 9, wherein the antigen is an alloantigen.

11. (Currently Amended) The method according to claim 9, further comprising a step of stimulating the T cells with an antigen prior to the contacting of step (a), thereby obtaining the activated T cells.

12. (Withdrawn) The method according to claim 11, wherein the antigen is an alloantigen.

13. (Withdrawn) The method according to claim 9, further comprising a step of stimulating T cells with anti-CD3 antibody and anti-CD28 antibody.

14. (Currently Amended) ~~An~~ Isolated, purified, and activated CD8<sup>+</sup> T cell ~~T cells~~ transduced with a foreign gene ~~prepared by the method according to claim 1~~ gene carried by a paramyxovirus vector.

15. (Currently Amended) The method according to claim 1, wherein ~~the contact is done with co-existence~~ step (a) comprises contacting the paramyxovirus vector carrying the gene with a mixture of naive CD8<sup>+</sup> T cells and activated CD8<sup>+</sup> T cells, thereby transducing a the gene into activated CD8<sup>+</sup> T cells with higher efficiency than naive CD8<sup>+</sup> T cells.

16-21. (Cancelled)

22. (New) The method according to claim 1, wherein step (b) comprises purifying activated T cells transduced with the gene.

23. (New) The method according to claim 1, wherein the activated T cells are activated CD8<sup>+</sup> T cells.

24. (New) The method according to claim 23, wherein the paramyxovirus vector is a Sendai virus vector.

25. (New) The method according to claim 23, wherein the activated CD8<sup>+</sup> T cells are antigen-activated CD8<sup>+</sup> T cells.

26. (New) The method according to claim 23, further comprising a step of stimulating CD8<sup>+</sup> T cells with an antigen prior to the contacting of step (a), thereby obtaining the activated CD8<sup>+</sup> T cells.

27. (New) The method according to claim 23, wherein step (a) comprises contacting the paramyxovirus vector carrying the gene with a mixture of naive CD8<sup>+</sup> T

cells and activated CD8<sup>+</sup> T cells, thereby transducing the gene into activated CD8<sup>+</sup> T cells with higher efficiency than naive CD8<sup>+</sup> T cells.

28. (New) The method according to claim 23, wherein step (b) comprises purifying activated CD8<sup>+</sup> T cells transduced with the gene.

29. (New) The isolated, purified, and activated T cells of claim 14, wherein the isolated, purified, and activated T cells are isolated, purified, and activated CD8<sup>+</sup> T cells, and wherein the isolated, purified, and activated CD8<sup>+</sup> T cells are prepared by the method according to claim 23.